Novartis Exelon Labeling Update Reflects Report Of Esophageal Rupture
Executive Summary
Novartis' revised labeling for the Alzheimer's agent Exelon (rivastigmine) directs that therapy should be reinitiated at the lowest daily dose following treatment interruption in order to reduce the risk of severe vomiting and esophageal rupture.